

Sunday 17 October

Pre-event		13:00-15:00
Presenter: Albertina Palelane		
A virtual welcome to Mozambique		
	Welcome message from the host organisation Leonardo Simão, Forum Local Organising Committee Chair and EDCTP High Representative Africa (Mozambique)	
	Welcome message from EDCTP Moses Bockarie, Forum Organising Committee Chair and EDCTP Director of Director of International Cooperation (Africa) & Head of Africa Office (South Africa)	
	Policy and strategic framework for future-oriented cooperation with EDCTP Armindo Tiago, Minister of Health of the Republic of Mozambique	
	Round-table: And overview of the Tenth EDCTP Forum <ul style="list-style-type: none"> Leonardo Simão, Forum Local Organising Committee Chair and EDCTP High Representative Africa (Mozambique) Moses Bockarie, Forum Organising Committee Chair and EDCTP Director of Director of International Cooperation (Africa) & Head of Africa Office (South Africa) Catherine Hankins, Forum Programme Committee Chair and EDCTP Scientific Advisory Committee Chair (Canada/The Netherlands) 	
	Closing remarks and key recommendations	

Monday 18 October

Pre-event		10:00-12:00
Presenter: Albertina Palelane		
Research Policy in Mozambique: the impact of the Health Research		10:00-11:00
Speakers:	<ul style="list-style-type: none"> Daniel Nivagara, Minister for Science, Technology and Higher Education (Mozambique) Ilesh Jani, Director General, National Health Institute (Mozambique) Alfredo Vergara, Country Director, Centers for Disease Control and Prevention (CDC, Mozambique) Francisco Saúte, Director General, Manhiça Health Research Centre, (Mozambique) Fernando Regulez, Spanish Agency for International Development Cooperation (Spain) 	
Chair: Leonardo Simão (Mozambique)		
Celebration of the 25th anniversary of the Manhiça Health Research Centre		11:00-12:00
Speakers:	<ul style="list-style-type: none"> Pedro Alonso, WHO Global Malaria Programme (Switzerland) Lídia Cardoso, Deputy Minister of Health of the Republic of Mozambique Alberto Cerezo, Ambassador of Spain Eusébio Macete, Manhiça Health Research Centre (Mozambique) Francisco Saúte, Manhiça Health Research Centre (Mozambique) Antoni Plasència, Director, Barcelona Institute for Global Health (ISGlobal, Spain) Michael Makanga, Executive Director, EDCTP (The Netherlands) 	
Networking groups		13:15-13:45

Meet the experts		13:15-13:45
Cultural performance		13:45-14:00
Plenary session I		14:00-16:00
Chairs: Michael Makanga (The Netherlands) and Leonardo Simão (Mozambique)		
Opening ceremony		14:00-14:55
	Leonardo Simão, Forum Local Organising Committee Chair and EDCTP High Representative Africa (Mozambique)	
	Catherine Hankins, Forum Programme Committee Chair and EDCTP Scientific Advisory Committee Chair (Canada/The Netherlands)	
	Yazan Yazdanpanah, EDCTP Board & General Assembly Chair (France)	
	Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, European Commission	
	Jutta Urpilainen, Commissioner for International Partnerships, European Commission	
	Soumya Swaminathan, Chief Scientist, World Health Organization (Switzerland)	
	Armindo Tiago, Minister of Health of the Republic of Mozambique	
Dr Pascoal Mocumbi Prize		14:55-15:10
Presenters:	• Leonardo Simão (Mozambique)	
Keynote addresses		15:10-16:00
Chair: Michael Makanga (The Netherlands)		
Presentation(s):	WHO strategy for achieving equity in health Lindiwe Makubalo, World Health Organization - Regional Office for Africa (Republic of Congo)	
	COVID-19 John Nkengasong, Africa CDC (Ethiopia)	
Exhibitor talks		16:00-16:15
Break		16:00-16:15
1.1 Parallel session		
TRACK A: Advancing biomedical interventions towards improved and equitable health		
Emerging and re-emerging diseases (COVID-19)		16:15-16:45
Chairs: Eric Delaporte (France) and Erika Gaspari (The Netherlands)		
A5-266	COVID-19 and Sudden Unexpected Community Deaths in Lusaka, Zambia, Africa – A Descriptive Medico-Legal Whole-Body Autopsy Case Series Luchenga Mucheleng'anga, Office of The State Forensic Pathologist (Zambia)	
A5-198	Field performance of a rapid antigen detection test for SARS-CoV-2 (COVID-19 Ag Respi-Strip) in two West African settings: the COVADIS study Fraçois Kiende, Institut De Recherche En Science De La Santé-Clinical Research Unit of Nanoro (Burkina Faso)	
1.2 Parallel session		
TRACK B: Equity challenges in cross-cutting issues		
Malaria vaccines, vaccine development and vaccination challenges		16:15-16:45
Chairs: Halidou Tinto (Burkina Faso) and Michelle Helinski (The Netherlands)		
B5-65	High efficacy of a low dose candidate malaria vaccine, R21 adjuvanted with Matrix-M™, with seasonal administration in children in Burkina Faso Hamtandi Magloire Natama, Institut De Recherche En Sciences De La Santé- Unité De Recherche Clinique De Nanoro (Burkina Faso)	

A3-364	Efficacy of Pfs230D1-EPA-AS01 Vaccine, a Transmission Blocking Vaccine against Plasmodium falciparum, assessed with a Direct Skin Feeding using Anopheles gambiae (coluzzi) in children 9-18 years old in Mali Issaka Sagara, University of Sciences Techniques and Technologies (Mali)	
1.3 Parallel session		
TRACK C: Addressing inequities in research		
Advancing women in global health science		16:15-16:45
Chairs: Marleen Temmerman (Kenya) and Tomás López-Peña Ordoñez (Spain)		
C2-048	Reducing Gender Disparity and Promoting Capacity Development among Women in Health Research through a Holistic Mentorship in Cameroon Marceline Djuidje Ngounoue, University of Yaoundé 1 (Cameroon)	
C2-085	Challenges in identifying female candidates from countries with limited research capacity for a research trainee fellowship: a case description from East Africa I. Marion Sumari-de Boer, Kilimanjaro Clinical Research Institute (Tanzania)	
1.4 Parallel session		
TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation		
Community engagement, ethics and human rights		16:15-16:45
Chairs: Paulo Ferrinho (Portugal) and Keymanthri Moodley (South Africa)		
D2-134	Capacity of Community Advisory Boards for Effective Community Engagement in Clinical Research: A Mixed Methods Study Levicatus Mugenyi, The Aids Support Organization (Uganda)	
C3-170	Barriers to accessing treatment among patients with r-HAT around Vwaza Marsh wildlife reserve in Northern Malawi Alister Munthali, University of Malawi (Malawi)	
Plenary session II		16:45-16:55
Outstanding Female Scientist Prize		16:45- 16:55
Presenter:	Catherine Hankins, Forum Programme Committee Chair and EDCTP Scientific Advisory Committee Chair (Canada/The Netherlands)	
WHO Special Session on malaria vaccines		17:00-18:30
Chairs: Benido Impouma (Republic of Congo), Rose Leke (Cameroon) and Inmaculada Peñas Jiménez (Belgium)		
Presentation(s):	<p>Welcome and introductions</p> <ul style="list-style-type: none"> Benido Impouma, Universal Health Coverage: Communicable and Noncommunicable Diseases, WHO Regional Office for Africa (Republic of Congo) Rose Leke, Faculty of Medicine and Biomedical Sciences, University of Yaoundé (Cameroon) Inmaculada Peñas Jiménez, EDCTP Policy Officer, European Commission <p>Overview of the global malaria situation</p> <ul style="list-style-type: none"> Pedro Alonso, WHO Global Malaria Programme (Switzerland) <p>RTS,S – the first malaria vaccine for use in African children</p> <ul style="list-style-type: none"> Patricia Njuguna, WHO Global Malaria Programme (Kenya) Kwaku Poku Asante, Kintampo Health Research Center (Ghana) Mary Hamel, WHO department of Immunization Vaccines and Biologicals (Switzerland) Abdisalan Noor, WHO Global Malaria Programme (Switzerland) <p>Other vaccines and new initiatives</p> <ul style="list-style-type: none"> Adrian Hill, Jenner Institute, University of Oxford (United Kingdom) Stephen L. Hoffman, Sanaria Inc (United States) Özlem Türeci, BioNTech SE (Germany) 	

Tuesday 19 October

Poster viewing	10:30-12:30
Networking groups	12:30-13:00
Meet the experts	12:30-13:00
1.1 Sponsored symposia	
TRACK A: Advancing biomedical interventions towards improved and equitable health	
Gender equity in health: Female genital schistosomiasis – a major challenge for women’s health in sub-Saharan Africa	13:00-14:00
Organiser(s):	Merck
Chair(s):	Jutta Reinhard-Rupp (Switzerland)
Presentation(s):	<p>Opening remark: The Power of Partnership to address health challenges and inequality Jutta Reinhard-Rupp, Merck (Switzerland)</p> <p>FGS Accelerated Scale-up Together (FAST): The FAST Program in Ghana and Madagascar Julie Jacobsen and Isis Umbelino, Bridges to Development (United States)</p> <p>Concerted action on FGS in Cameroon: Integrating precision mapping of urogenital schistosomiasis with rapid assessment of FGS for better community management of gynecological diseases Sandrine Nyotue, Centre International de Recherches, d’Enseignements et de Soins (CIRES, Cameroon)</p> <p>New dosage of praziquantel to treat FGS: first results from the PoC/Phase II clinical trial in Madagascar Bodo Sahondra Randrianasolo, Association K’OLO VANONA (Madagascar)</p>
1.2 Sponsored symposia	
TRACK: A: Advancing biomedical interventions towards improved and equitable health	
Main post-approval and real-life studies conducted and ongoing in parallel with the launch and scale-up of Pyramax in Africa	13:00-14:00
Organiser(s):	Medicines for Malaria Venture (MMV, Switzerland)
Chair(s):	Isabelle Borghini (Switzerland) and Kassoum Kayentao (Mali)
Presentation(s):	<p>Pyramax® (pyronaridine-artesunate) Clinical Development: WANECAM & CANTAM Stephan Duparc, MMV (Switzerland)</p> <p>Efficacy and safety of Pyronaridine-Artesunate (Pyramax®), a Newly-recommended Artemisinin-based Combination for the Treatment of Malaria infection in African Pregnant Women Kassoum Kayentao, PYRAPREG Project Coordinator, Malaria Research and Training Center Department of Epidemiology of Parasitic Diseases Faculty of Pharmacy University of Sciences Techniques & Technology Bamako (Mali)</p> <p>Comparative efficacy and safety of pyronaridine-artesunate versus artemetherlumefantrine in the treatment of acute uncomplicated malaria among children in south-west Nigeria Catherine Falade, Department of Pharmacology & Therapeutics, College of Medicine, University of Ibadan (Nigeria)</p>
1.3 Sponsored symposia	
TRACK C: Addressing inequities in research	
Equal Voices: Addressing Inequities in Global Health Research Participation	13:00-14:00
Organiser(s):	European Global Health Research Institutes Network (EGHRIN, the Netherlands)

Chair(s):	Richard Horton (United Kingdom)
Presentation(s):	<p>Equity in agenda definition in global health research between Europe and partner countries - a view from the European Commission Barbara Kerstiëns, European Commission</p> <p>How to better achieve gender balance Jolene Skordis, University College London (United Kingdom)</p> <p>Achieving equity in global health research between the Global North and South Catherine Kyotubungi, African Population and Health Research Center (Kenya)</p>

1.4 Sponsored symposia

TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation

Fostering a stronger collaboration in personalised medicine: The EU-Africa PerMed project 13:00-14:00

Organiser(s):	Instituto de Salud Carlos III (ISCIII, Spain)
Chair(s):	Joaquín Guinea (Spain) and Souleymane Mboup (Senegal)
Presentation(s):	<p>The EU-Africa PerMed project Joaquin Guinea, InnovaTec (Spain)</p> <p>The Personalised Medicine research and innovation landscape in Africa: results of the EU-Africa PerMed scientific and policy mapping work Erika Sela, InnovaTec (Spain) and Amr Radwan, Egyptian Center of Innovation and Technology Development (ECITD, Egypt)</p> <p>Challenges and opportunities of personalised medicine for Africa Rizwana Mia, South African Medical Research Centre (South Africa)</p>

2.1 Parallel session

TRACK A: Advancing biomedical interventions towards improved and equitable health

HIV 14:00-14:45

Chairs: Collen Masimirembwa (Zimbabwe) and Pauline Beattie (The Netherlands)

A1-131	<p>The DREAMM (Driving REduced Meningoencephalitis Mortality) Project: Initial Results from Tanzania Sayoki Mfinanga, National Institute For Medical Research, Muhimbili Centre (Tanzania)</p>
A1-297	<p>A Phase 3, Open-label, Dose Escalation study to determine the pharmacokinetics of Atazanavir administered with Rifampicin to HIV positive adults on second-line ART regimen with suppressed HIV-1 viral load (DERIVE): Scheduled Interim Analysis Kamunkhala Gausi, University of Cape Town (South Africa)</p>
A1-127	<p>HIV acquisition risk in exposed infants delivered preterm Gbolahan Ajibola, Botswana Harvard Aids Institute (Botswana)</p>

2.2 Parallel session

TRACK A: Advancing biomedical interventions towards improved and equitable health

Respiratory infections and diarrhoeal diseases 14:00-14:45

Chairs: Martin Meremikwu (Nigeria) and Moses Bockarie (South Africa)

A6-354	<p>Loss of recognition of SARS-CoV-2 beta variant spike epitopes but overall preservation of T cell immunity Wendy Burgers, University of Cape Town (South Africa)</p>
A6-330	<p>Genetic diversity of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in the Republic of Congo Claujens Chastel Mfoutou Mapanguy, Fondation Congolaise Pour La Recherche Médicale (Congo)</p>

2.3 Parallel session

TRACK B: Equity challenges in cross-cutting issues	
Vaccine development and vaccination challenges	14:00-14:45
Chairs: Richard Adegbola (Nigeria) and Debora Bade (The Netherlands)	
B5-141	Nested thematic analysis of mothers' reasons for withdrawal of consent to participate in a rotavirus vaccine clinical trial among mother-infant pairs in Zambia Yvonne Kumwimba Mutombo, Centre for Infectious Diseases Research in Zambia (Zambia)
B5-199	Active safety surveillance of Human Papilloma Virus (HPV) Vaccine in Addis Ababa, Ethiopia Tigist Dires Gebreyesus, Ethiopian Food and Medicine Authority/ Karolinska Institutet (Ethiopia)
B5-251	A phase 1 age descending placebo controlled clinical trial to examine the safety, tolerability, and immunogenicity of an oral inactivated ETEC Vaccine (ETVAX®) with dmlT adjuvant in healthy adults and children in Zambia Nsofwa Sukwa, Centre for Infectious Disease Research in Zambia (Zambia)
2.4 Parallel session	
TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation	
Partnerships and alliances to enhance coordination, collaboration, and cooperation	14:00-14:45
Chairs: Juliet Nabyonga Orem (Zimbabwe) and Thomas Nyirenda (South Africa)	
D1-098	Institutional and legislative impact of BERC-Luso in Portuguese speaking African partner countries Maria do Céu Patrão Neves, BERC-Luso (Portugal)
D1-181	Towards a new equitable collaborative norm – strengthening capacity building efforts of health research partnerships Kirsty Kaiser, Council on Health Research for Development (COHRED, Switzerland)
D1-106	Actions for fostering equitable cross-disciplinary global health research in practice Yan Ding, Liverpool School of Tropical Medicine (United Kingdom)
1.1 Oral poster presentations	
TRACK A: Advancing biomedical interventions towards improved and equitable health	
Emerging and re-emerging diseases	14:45-15:15
Chairs: Christine Stabell Benn (Denmark) and Jean Marie Habarugira (The Netherlands)	
A5-324	Yield of COVID-19 cases from a door-to-door symptom-based active case finding strategy Thomas Gachie, Zambart (Zambia)
A5-052	Prognostic value of CRP in SARS-CoV-2 infection: A simplified Biomarker of COVID-19 Severity in Sub-Saharan Africa Dawit Wolday, Mekelle University College of Health Sciences (Ethiopia)
A5-321	Lessons learned from using different diagnostic tools to identify community SARS-CoV-2 infection in Zambia Maria Ruperez, London School of Hygiene & Tropical Medicine (LSHTM, United Kingdom)
A5-259	Evaluation of Diagnostic Performance of four Commercial COVID-19 Rapid IgM and IgG Antibody Diagnostic Assays in Ethiopia Teklay Gebrecherkos, Mekelle University College of Health Sciences (Ethiopia)
C3-293	Developing a COVID-19 Community Epidemic Preparedness Plan: Lessons learned from an urban community in Zambia Musonda Simwinga, Zambart (Zambia)
1.2 Oral poster presentations	
TRACK B: Equity challenges in cross-cutting issues	
Cross-cutting issues in pandemics	14:45-15:15
Chairs: Peter Smith (United Kingdom) and Isabel Reis (The Netherlands)	
B7-128	IBBM: Strengthening biosafety and biosecurity capacities in Madagascar in times of COVID-19 Jean-Marc Kutz, BNITM (Germany)

B7-142	Impact of SARS-COV-2 pandemic on antiretroviral drug pick-up at a large treatment centre in Lagos, Nigeria Susan Adaba, Nigerian Institute of Medical Research (Nigeria)
B7-123	Effect of COVID-19 pandemic Implementing malaria mass test, treat and track in Ghana Ndong Ignatius Cheng, University of Ghana, Noguchi Memorial Institute For Medical Research (Ghana)
B7-185	Effective measures to approach a clinical trial development during the COVID-19 pandemic: the EDCTP-funded EMPIRICAL trial experience Cinta Moraleda, Servicio Madrileño de Salud (SERMAS, Spain)

1.3 Oral poster presentations

TRACK B: Equity challenges in cross-cutting issues

Vaccine development and vaccination challenges

14:45-15:15

Chairs: Michael Ramharter (Germany) and Michelle Helinski (The Netherlands)

A3-366	Safety and tolerability of Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine against <i>Plasmodium falciparum</i>, in healthy Malian Abdoulaye Katile, Malaria Research and Training Center (MRTC, Mali)
B5-327	Distribution of histo-blood group antigens among rotavirus vaccinated infants in Zambia Adriace Chauwa, Centre for Infectious Disease Research in Zambia (Zambia)
B5-340	A Pediatric Phase I/II age de-escalation dose-finding study for development of a vaccine against invasive non-typhoidal salmonellosis in sub-Saharan Africa Donata Medagliani, Sclavo Vaccines Association (Italy)
A5-160	Trends of SARS-CoV-2 pandemic, testing capacity, policy response and vaccination uptake in nine countries in sub-Saharan Africa: a cross-country analysis Abdinasir Yusuf Osman, PANDORA-ID-NET (United Kingdom)
A5-162	A Phase 1/2, randomized, controlled open-label trial to evaluate the safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus vaccine candidate in healthy children aged 1 to 12 years and in their adults and/or children relatives living in Lambaréné, Gabon Armel Vivien Ndong Mbouna, Cermel (Gabon)

1.4 Oral poster presentations

TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation

Capacity strengthening of institutions

14:45-15:15

Chairs: Christian Burri (Switzerland) and Nuraan Fakier (South Africa)

D5-352	A qualitative study on health facility utilization of GeneXpert machines for TB diagnosis in Tanzania Doreen Pamba, National Institute for Medical Research- Medical Research-Mbeya Medical Research Centre (NIMR-MMRC, Tanzania)
C4-219	FIND Integrated Biobanks (FIB) and Virtual Biobank Directory (VBD): a framework for equitable sample access and distribution to facilitate diagnostic research and development Warren Fransman, FIND (Switzerland)
D5-163	Research Capacity Strengthening Programme for (Re)-Emerging Infectious Diseases Control in Tanzania (REMODEL_TZ) Consortium: Effect on local research leadership Stellah Mpagama, Kibong'oto Infectious Diseases Hospital (Tanzania)
D5-189	The ENABLE Lassa Research Programme in West Africa – a major opportunity to strengthen site and investigator capacity to conduct vaccine trials and address Lassa fever knowledge gaps Donald Grant, Kenema General Hospital (Sierra Leone)
D5-322	The Global Health Training Centre: breaking barriers to research skills training and enabling access to those who need it the most Lauren Whelan, The Global Health Network (UK)

Exhibitor talks

15:15-15:45

Break		15:45-16:00
3.1 Parallel session		
TRACK A: Advancing biomedical interventions towards improved and equitable health		
Tuberculosis		16:00-17:00
Chairs Eric Delaporte (France) and Harleen Grewal (Norway)		
A2-087	Diagnostic accuracy of the Cepheid 3-gene Host Response fingerstick blood test in HIV+ and HIV- individuals in a prospective, multi-site study: interim results Jayne Sutherland, Medical Research Unit The Gambia at LSHTM (The Gambia)	
A2-112	Rapid Enumeration and Diagnostic for <i>M. Tuberculosis</i> (READ-TB) a low-cost molecular assay to enumerate <i>M. tuberculosis</i> in sputum for LMIC Isobella Honeyborne, University College London (United Kingdom)	
A2-093	Preliminary 18F FDG PET-CT image analysis from the PredictTB trial Stephanus Malherbe, Stellenbosch University (South Africa)	
3.2 Parallel session		
TRACK A: Advancing biomedical interventions towards improved and equitable health		
Malaria		16:00-17:00
Chairs Halidou Tinto (Burkina Faso) and Montserrat Blazquez-Domingo (The Netherlands)		
A3-283	Intermittent preventive treatment with dihydroartemisinin-piperazine with and without azithromycin versus sulphadoxine-pyrimethamine to reduce malaria-associated adverse pregnancy outcomes in Africa: a placebo-controlled trial Madanitsa Mwayiwawo, College of Medicine, University of Malawi (Malawi)	
A3-025	Cohort event monitoring study of 8572 malaria cases to evaluate, in real-world setting, the safety, tolerability and effectiveness of the fixed-dose combination therapy pyronaridine-artesunate for the treatment of uncomplicated malaria: the CANTAM study Lia Betty Dimessa Mbadinga, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon)	
A3-227	Community access to rectal artesunate for malaria (CARAMAL): observational research in Nigeria, Uganda and DR Congo Christian Burri, Swiss Tropical and Public Health Institute (Switzerland)	
A3-338	Optimizing the impact of Seasonal Malaria Chemoprevention: improving delivery and building capacity for evaluation: an update on project progress Jean-Louis Ndiaye, University of Thies (Senegal)	
3.3 Parallel session		
TRACK A: Advancing biomedical interventions towards improved and equitable health		
Neglected Infectious Diseases		16:00-17:00
Chairs: Jutta Reinhard-Rupp (Switzerland) and John Gyapong (Ghana)		
A4-188	Development and validation of a portable, point-of-need Mycobacterium ulcerans qPCR test Venus N.B. Frimpong, Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR, Ghana)	
A4-021	Micro-molecular epidemiology of Mycobacterium ulcerans revealed by VNTR-genotyping in Buruli ulcer endemic communities of the Nyong valley in Cameroon Francis Zeukeng, The Biotechnology Centre, University of Yaounde 1 (Cameroon)	
A4-032	Pediatric Praziquantel Consortium Program: From Concept to Practice Jutta Reinhard-Rupp, Merk (Switzerland)	
A4-050	Loop-Mediated Isothermal Amplification Assay for the Diagnosis and Monitoring of Anti-leishmanial Treatment Efficacy in Patients with or without HIV-1 Co-Infection Dawit Hagos, Mekelle University College of Health Sciences (Ethiopia)	
3.4 Parallel session		
TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation		
Ethics and human rights		16:00-17:00
Chairs: Paulo Ferrinho (Portugal) and Juliet Nabyonga Orem (Zimbabwe)		

D2-064	Tackling health inequities through gender mainstreaming in research ethics: the West African experience Farah Nabil, University of Zaragoza (Spain)	
D2-222	Scaling up Capacity of Research Ethics Committees in Uganda Maxwell Otim Onapa, Ministry of Science, Technology and Innovation (Uganda)	
D2-068	Ethical Challenges for Clinical Trials in Cabo Verde Isabel Inês Monteiro de Pina Araújo, University of Cabo Verde	
D2-166	Is consent into clinical trials for life-threatening illnesses truly voluntary and informed? Findings and recommendations from a qualitative study embedded within the AMBITION-cm trial for HIV-associated cryptococcal meningitis. David Lawrence, London School Of Hygiene And Tropical Medicine (UK)	
Plenary session III		17:00-18:35
Chair: Ilesh Jani (Mozambique)		
Keynote addresses		17:00-17:25
Presentation(s):	Science diplomacy Leonardo Simão, EDCTP High Representative for Africa (Mozambique)	
Scientific Leadership Prize		17:25-17:35
Presenter:	Marleen Temmerman (Kenya)	
Debate: Equity in innovation, partnership, and research is a desirable but unrealistic goal		17:35-18:35
Moderator: Catherine Hankins (Canada/The Netherlands)		
Speakers:	<ul style="list-style-type: none"> • Keymanthri Moodley, Stellenbosch University, South Africa • Carel Ijsselmuiden, Council on Health Research for Development (COHRED, Switzerland) • Eusebio Macete, Mozambique Pharmacies, Farmac and Manhiça Foundation (Mozambique) • Cissy Kityo, Joint Clinical Research Centre (JCRC, Uganda) 	

Wednesday 20 October

Poster viewing	10:30-12:30
Networking groups	12:30-13:00
Meet the experts	12:30-13:00
2.1 Sponsored symposia	
TRACK A: Advancing biomedical interventions towards improved and equitable health (Malaria)	
Advances in Intermittent Preventive Treatment of malaria in infants (IPTi) for improved and equitable health for children under 2 in sub-Saharan Africa	13:00-14:00
Organiser(s):	Barcelona Institute for Global Health (ISGlobal)
Chair(s):	Clara Menendez (Spain)
Presentation(s):	<p>Lessons learned after 4 years of IPTi implementation in Sierra Leone Augustin Fombah, ISGlobal and Ministry of Health of Sierra Leone (Sierra Leone)</p> <p>Challenges in the implementation of IPTi in a country with different malaria transmission patterns Francisco Saúte, Manhica Health Research Centre (CISM, Mozambique)</p> <p>Overview of the MULTIPLY (MULTIple doses of IPTi Proposal: a Lifesaving high Yield intervention) project in Mozambique, Togo and Sierra Leone Clara Menendez, ISGlobal (Spain)</p>
2.2 Sponsored symposia	
TRACK B: Equity challenges in cross-cutting issues (Pharmacovigilance)	
Equity in safety: improving pharmacovigilance of drugs and vaccines in Africa	13:00-14:00
Organiser(s):	Amsterdam Institute for Global Health and Development (PAVIA) & Karolinska Institutet (PROFORMA)
Chair(s):	Sten Olsson (United Kingdom) and Margareth Ndomondo-Sigonda (South Africa)
Presentation(s):	<p>Strengthening Pharmacovigilance in mass drug administration and immunization programs: experience from the PROFORMA project Eleni Aklillu, Karolinska Institute (Sweden)</p> <p>Making safety surveillance work: Lessons learnt from the PAVIA project Yohanna Avong, Institute of Human Virology (Nigeria)</p> <p>COVID-19 vaccine safety surveillance in Africa Sujeet Kumar Jain, WHO-AFRO (Republic of Congo)</p>
2.3 Sponsored symposia	
TRACK C: Addressing inequities in research (Equity challenges)	
Addressing equity challenges in health for neglected populations	13:00-14:00
Organiser(s):	Drugs for Neglected Diseases <i>Initiative</i> (DNDi)
Chair(s):	Nathalie Strub-Wourgaft (Switzerland)
Presentation(s):	<p>Progress and challenges in meeting the NTD Roadmap goals Anthony Solomon, World Health Organization (WHO, Switzerland)</p> <p>Human African trypanosomiasis: New treatments for the population at risk Antoine Tarral, DNDi (Switzerland)</p> <p>Improving cryptococcal meningitis treatment therapies for people living with HIV Isabela Ribeiro, DNDi (Switzerland)</p>

	New treatments to respond to the needs of neglected patients affected with leishmaniasis Fabiana Alves, DNDi (Switzerland)
--	--

2.4 Sponsored symposia

TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation (Partnership and alliances to enhance coordination, collaboration and cooperation)

Advocacy challenges and opportunities for stepping up support for poverty-related and neglected disease R&D after COVID-19	13:00-14:00
---	-------------

Organiser(s):	Deutsche Stiftung Weltbevölkerung (DSW)
Chair(s):	Agustin Martin Lasanta (Belgium)
Presentation(s):	<p>Introduction: EU-Africa tools on epidemic preparedness and PRND R&D Agustin Martin, DSW (Belgium)</p> <p>A more enabling environment for PRND R&D in Africa: challenges & opportunities Bartholomew Dicky Akanmori, WHO-AFRO (Republic of Congo)</p> <p>Funding for neglected disease R&D: risks, opportunities and expectations Nick Chapman, Policy Cures Research (Australia)</p> <p>Highlighting the value of PRND R&D during the COVID-19 pandemic Marleen Temmerman, Aga Khan University (Kenya)</p> <p>The EDCTP3 Strategic Research Agenda: harnessing COVID's momentum to advance PRND R&D Catherine Hankins, Amsterdam Institute for Global Health and Development (Canada/The Netherlands)</p>

Plenary session IV

14:00-14:50

Chair: Marcel Tanner (Switzerland) and Eusébio Macete (Mozambique)

Keynote addresses

	COVID-19 Maternal Immunization prioritization and implications for pharmacovigilance: the case of Mozambique Esperança Sevene, Eduardo Mondlane University (Mozambique)
	A journey with AREF: Enhancing Health Research Capacity Development in Africa Tumani Corrah, Africa Research Excellence Fund (AREF, United Kingdom and The Gambia)

2.1 Oral poster presentations

TRACK A: Advancing biomedical interventions towards improved and equitable health

Malaria	14:50-15:20
----------------	-------------

Chairs: Peter Smith (United Kingdom) and Lara Pandya (The Netherlands)

A3-088	Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia Edgard Dabira, MRC Unit The Gambia at LSHTM (The Gambia)
A3-083	Effect of intermittent preventive treatment of malaria with artemisinin-based combination therapies on schoolgirls versus boys in Mali Hamma Maiga, Institut National de Sante Publique (Mali)
A3-298	Update from the MULTIPLY EDCTP2 project to deliver multiple doses of IPTi through the EPI platform for the prevention of malaria in children under 2 Francisco Saúte, Manhiça Health Research Center (Mozambique)
A3-108	White blood cell counts and C-reactive protein as diagnostic tools to support the sequential interpretation of malaria rapid diagnostic test detecting PfHRP2 and pLDH antigens for the management of febrile diseases in rural setting

François Kiemde, Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN, Burkina Faso)

2.2 Oral poster presentations

TRACK B: Equity challenges in cross-cutting issues

Pharmacovigilance

14:50-15:20

Chairs: Richard Adegbola (Nigeria) and Michelle Nderu (South Africa)

A3-278	Using population-based structures to actively monitor AEFI with Measles Rubella and Polio during a mass immunisation campaign Dan Kajungu, Makerere University Centre for Health and Population Research (MUCHAP, Uganda)
A3-061	Assessment of the pharmacovigilance systems within the national immunization programs in Ethiopia, Kenya, Rwanda, and Tanzania Abbie Barry, Karolinska Institutet (Sweden)
A3-304	The safety of artemether-lumefantrine related to day 7 lumefantrine concentration after repetitive treatment of uncomplicated malaria cases during two years in Mali Mamadou Tekete, Malaria Research and Training Center (Mali)
A3-277	The Uganda COVID-19 Vaccine Safety monitoring (UgVacSafe) – An active surveillance platform Dan Kajungu, Makerere University Centre for Health and Population Research (MUCHAP, Uganda)
A3-252	Impact of an Educational intervention on Pharmacovigilance knowledge among health care providers at Kilimanjaro Christian Medical Centre, Moshi, Tanzania Eva Muro, Kilimanjaro Christian Medical Centre (Tanzania)

2.3 Oral poster presentations

TRACK C: Addressing inequities in research

Community engagement and good participatory practice in research

14:50-15:20

Chairs: Juliet Nabyonga-Orem (Zimbabwe) and Martin Meremikwu (Nigeria)

C3-045	Participants' perspectives of engaging in clinical trials in Uganda; a cross-sectional study Collins Agaba, The AIDS Support Organization (TASO, Uganda)
C3-169	Community perceptions and pathways to care for rhodesiense human African trypanosomiasis (r-HAT) in Kaberamaido, Eastern Uganda: Implications for treatment access and case detection Stella Neema, Makerere University (Uganda)
A5-172	Door-to-door active screening using rapid diagnostic tests for monitoring human African trypanosomiasis in South-West Burkina Faso Charlie Franck Alfred Compaoré, University Nazi Boni and Centre International de recherche-développement sur l'élevage en zone subhumide (Burkina Faso)
C3-143	A two-day workshop on Controlled Hookworm Human Infection (CHHI) held in Lambaréné, Gabon: challenges towards mutual engagement between sub-Saharan African scientists and policymakers to enhance the uptake of research benefits and public literacy in biomedical research Pamela Catherine Angoissa Minsoko, Centre de Recherches Médicales de Lambaréné (CERMEL, Gabon)
C3-102	Health Data Research West Africa (HDR-WA): Building a strategy for new and better science through sharing of clinical research data Dondeh Bai Lamin, Medical Research Council at the London School of Hygiene and Tropical Medicine (The Gambia)

2.4 Oral poster presentations

TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation

Partnerships and alliances to enhance coordination, collaboration, and cooperation

14:50-15:20

Chairs: Marleen Temmerman (Kenya) and Christian Burri (Switzerland)

D1-320	The Trials Methodology Research Partnership: achievements and way forward Elizabeth Allen, University of Cape Town (South Africa)
--------	---

D1-300	The establishment of A European-African network for strengthening the regulatory capacity for clinical research and pharmacovigilance in Central Africa: the Africlinique project Dario Scaramuzzi, R-evolution Worldwide (Italy)
D1-347	REECAO (Renforcement de l’Ethique des Essais Clinique en Afrique de l’Ouest/Reinforcing clinical trials ethics in west Africa): a network of national and institutional ethical committees in West Africa Karim Traore, Malaria Research and Training Center (Mali)
D1-312	The power from within: research networks as mechanisms for delivering high-impact research training Ken Awuondo, The Global Health Network, University of Oxford (United Kingdom)
D1-105	Health research ethics and medicines regulatory capacities: lessons and progress made from an audit of research ethics committees and regulatory pharmacovigilance centres Ruby Doryn Mcharo, National Institute for Medical Research - Mbeya Medical Research Centre (NIMR-MMRC, Tanzania)

Break	15:20-15:30
--------------	-------------

Exhibitor talks	15:20-15:30
------------------------	-------------

4.1 Parallel session

TRACK A: Advancing biomedical interventions towards improved and equitable health

Emerging & re-emerging diseases (non-COVID-19)	15:30-16:30
---	-------------

Chairs: Thomas Nyirenda (South Africa) and Jean Marie Vianney Habarugira (The Netherlands)

A5-075	Sero-prevalence of arthropod-borne viral infections among Lukanga swamp residents in Zambia Caroline Chisenga, Centre for Infectious Disease Research in Zambia
A5-030	The burden and associated risk factors of chikungunya, dengue and Zika in Tanzania Leonard Mboera, SACIDS Foundation for One Health (Tanzania)
A5-333	Clinical presentation of Congenital Syphilis, in a rotavirus vaccine cohort study in Lusaka: a case series report Nsofwa Sukwa, Centre for Infectious Disease Research in Zambia
A5-132	High prevalence of fungemia at two National Referral Hospitals in a developing country setting Beatrice Achan, Makerere University (Uganda)

4.2 Parallel session

TRACK D: Equity challenges in cross-cutting issues

Innovation and opportunities in capacity strengthening: lessons from research in pandemics	15:30-16:30
---	-------------

Chairs: Pauline Beattie (The Netherlands) and Tomas López-Peña Ordoñez (Spain)

D8-118	A dermatological mHealth tool for Sub-Sahara African health workers: the diagnostic accuracy and reproducibility of the third version of NLR’s SkinApp Nelly Mwageni, Catholic University of Health and Allied Sciences (Tanzania)
D8-220	Strengthening epidemiological surveillance in Benin and Burkina Faso for an effective response to COVID 19 Gilles Cottrell, Institute of Research for Sustainable Development (IRD, France)
D8-253	A Community of Practice for addressing global research inequity and evolving priorities during the COVID-19 Pandemic Nicole Feune de Colombi, The Global Health Network, Centre for Tropical Medicine & Global Health, University of Oxford (United Kingdom)
D8-150	Mapping of Clinical Trials and Their Community Engagement Approaches in Uganda; A Situational Analysis Andrew Ojok Mijumbi, The AIDS Support Organisation (TASO, Uganda)

4.3 Parallel session

TRACK C: Addressing inequities in research	
Innovations and lessons learned from pandemics to address inequities	15:30-16:30
Chairs: Moses Bockarie (South Africa) and Christine Stabell Benn (Denmark)	
C5-294	Seeing is believing: community perceptions and experiences of COVID-19 over time in an urban community in Zambia Musonda Simwinda, Zambart (Zambia)
C5-115	The global case-fatality rate of Covid-19 has been declining disproportionately between top-vaccinated countries and the rest of the world Najmul Haider, The Royal Veterinary College (United Kingdom)
C5-074	Comparable SARS-CoV-2 exposure in young children and healthcare workers in Zambia Natasha Laban, Centre for Infectious Disease Research in Zambia
C5-325	Evaluation of diagnostic tests for the screening and management of COVID-19 in Zambia (RapidCoV) Dr Franklyn Nkongho, School of Life sciences, University of Lincoln (United Kingdom).

4.4 Parallel session

TRACK D: Capacity strengthening, collaborations, enhancing the research environment, knowledge translation	
Fostering the next generation of African scientists	15:30-16:30
Chairs: John Gyapong (Ghana) and Jutta Reinhard-Rupp (Switzerland)	
C4-249	Capacity strengthening of research laboratory staff: providing equitable support Russel Dacombe, Liverpool School of Tropical Medicine (United Kingdom)
A4-168	AfriKADIA (RIA2016S-1635) – Challenges and lessons learnt in carrying out a Phase 3 multi-country clinical trial Alexandra Solomos, Drugs for Neglected Diseases <i>Initiative</i> (DNDi, Switzerland)
D5-174	Building Capacity for Internationally Recognized Research- The EACCR2 story Bernard Kikaire, Uganda National Health Research Organisation/Uganda Virus Research Institute (Uganda)
D1-099	A scoping review of the guidance on North South research partnerships Shirine Voller, London School of Hygiene & Tropical Medicine (United Kingdom)

3.1 Oral poster presentations

TRACK A: Advancing biomedical interventions towards improved and equitable health	
HIV	16:30-17:00
Chairs: Michelle Singh (South Africa) and Paulo Ferrinho (Portugal)	
A1-221	Effectiveness of Option B+ in preventing mother-to-child transmission of HIV through qualitative detection of viral nucleic acid in infants Tatiana Noumi, Military Health Research Centre (Cameroon)
A1-285	Sensitivity and Specificity in Predicting viral load suppression by Self-reported adherence, Pharmacy Refills and Real Time Medication Monitoring among PLHIV living in Tanzania Kennedy Ngowi, Kilimanjaro Clinical Research Institute (Tanzania)
A1-231	'I prefer to take pills when I plan to have sex'; perceptions of on-demand versus daily pre-exposure prophylaxis among adolescents at high risk of HIV infection in Kampala, Uganda Yunia Mayanja, MRC/UVRI & LSHTM Uganda Research Unit (Uganda)
A1-246	High performance of integrase genotyping on diverse HIV-1 clades circulating in Cameroon: toward a successful transition to dolutegravir-based regimens in low and middle-income countries Ezechiel Ngoufack Jagni Semengue, Centre International De Référence Chantal Biya (Cameroon)
A1-024	Advanced HIV disease among pregnant women at antenatal care enrolment in Southern Mozambique Tacilta Helena Francisco Nhampossa, Centro de Investigação em Saúde de Manhiça (Mozambique)

3.2 Oral poster presentations

TRACK A: Advancing biomedical interventions towards improved and equitable health	
Tuberculosis	16:30-17:00

Chairs: Richard Adegbola (Nigeria) and Harleen Grewal (Norway)	
A2-031	Validation of host cerebrospinal fluid protein biosignatures for early diagnosis of tuberculous meningitis in children Charles Manyelo, Stellenbosch University (South Africa)
A2-339	Lung Function Evaluation in Children with Presumptive TB - The RaPaed-AIDA-TB Cohort Denise Banze, Instituto Nacional de Saúde/Centro de Investigação e Treino da Polana Caniço (Mozambique)
A2-182	Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis Novel Chegou, Stellenbosch University (South Africa)
A2-096	Multi-Biomarker Test strip for POC TB Triage using fingerstick blood Paul Corstjens, Leiden University Medical Center (The Netherlands)
A2-113	Biomarkers for pericardial TB diagnosis and monitoring of TB treatment response in HIV infected individuals Hygon Mutavhatsindi, University of Cape Town (South Africa)

3.3 Oral poster presentations

TRACK A: Advancing biomedical interventions towards improved and equitable health

Malaria	16:30-17:00
----------------	-------------

Chairs: Peter Smith (United Kingdom) and Michelle Nderu (The Netherlands)

A3-276	Safety and efficacy of Dihydroartemisinin-Piperaquine for Seasonal Malaria Chemoprevention in school aged children, Mali: a double-blind randomized controlled non-inferiority trial Karim Traore, Malaria Research and Training Center (Mali)
A3-228	Safety and efficacy of a single low-dose of primaquine for treatment of uncomplicated <i>Plasmodium falciparum</i> malaria based on cytochrome P450 2D6 activity in Bagamoyo district, Tanzania Richard Mwaiswelo, Tropical Pesticides Research Institute (Tanzania)
A3-290	Long-term selection of molecular resistance markers by piperaquine: warning signals for the future of dihydroartemisinin-piperaquine in Africa Leyre Pernaute Lau, Karolinska Institutet (Sweden)
A3-234	Genetic background and pfkclh13 polymorphisms in <i>Plasmodium falciparum</i> parasite population in high malaria transmission settings in Uganda Moses Ocan, Makerere University, College of Health Sciences (Uganda)
A3-361	Update on the West African Network for Clinical Trials of Antimalarial Drugs 2 (WANECAM 2) Abdoulaye Djimde, University of Science, Techniques and Technologies of Bamako (Mali)

3.4 Oral poster presentations

TRACK B: Equity challenges in cross-cutting issues

Co-infections and co-morbidities	16:30-17:00
---	-------------

Chairs: Michael Ramharter (Germany) and Juliet Nabyonga-Orem (Zimbabwe)

A3-191	Pharmacokinetic assessment of dihydroartemisinin-piperaquine (DHA-PPQ) administered as Intermittent Preventive treatment (IPTp) to HIV-infected pregnant women on antiretroviral drugs and cotrimoxazole prophylaxis: a sub-study of the EDCTP2- MAMAH project Lia Betty Dimessa Mbadinga, Barcelona Institute for Global Health (Spain)
B1-326	Interim report of the ParCam (Contribution of intestinal parasite infections in the risk of developing cardio-metabolic diseases in rural and urban areas of Gabon: a pilot study) study Marielle Karine Bouyou, La Faculté de Médecine Université des Sciences de la Santé (Gabon)
B1-329	Firmicutes Predominate the Skin Microbiota Among Individuals Presenting LF Pathology Samuel Asiedu, Kwame Nkrumah University of Science and Technology (Ghana)
B1-303	Impact of intermittent preventive treatment with monthly sulfadoxine-pyrimethamine versus monthly dihydroartemisinin-piperaquine, with or without a single course of azithromycin, on the intestinal and vaginal microbiomes of pregnant women in Tanzania and Malawi Matthew Chico, London School of Hygiene & Tropical Medicine (United Kingdom)
A3-190	Caring for African women: progress and main achievements of the EDCTP2- MAMAH project for malaria prevention among HIV-infected pregnant women from Gabon and Mozambique Raquel Gonzalez, Barcelona Institute for Global Health (Spain)

Plenary session V		17:00-18:15
Chairs: Ilesh Jani (Mozambique) and Francisco Saúte (Mozambique)		
Outstanding Research Team Prize		17:00-17:10
Presenter:	Ilesh Jani, Ministry of Health (Mozambique)	
Keynote address		17:10-17:35
EDCTP – A Blueprint for International Cooperation in Global Health?		
Andrea Spelberg, German Federal Ministry of Education and Research (BMBF, Germany)		
Closing ceremony		17:35-18:15
Speakers:	<ul style="list-style-type: none"> • Michael Makanga, EDCTP Executive Director (The Netherlands) • Leonardo Simão, Forum Local Organising Committee Chair and EDCTP High Representative (Africa) (Mozambique) • Catherine Hankins, Forum Programme Committee Chair and EDCTP Scientific Advisory Committee Chair (Canada/The Netherlands) • Moses Bockarie, Forum Organising Committee Chair and EDCTP Director of International Cooperation (Africa) & Head of Africa Office (South Africa) • Marcel Tanner, EDCTP High Representative (Europe) (Switzerland) • Antonio Sánchez-Benedito Gaspar, Ambassador, Head of Delegation, Delegation of the European Union to the Republic of Mozambique (Mozambique) • Armindo Tiago, Minister of Health of the Republic of Mozambique (Mozambique) 	
Cultural performance		18:15-18:30

Thursday 21 October

Workshops		10:00-14:00
Moving from principles to practice: Barriers and enablers to equitable research partnerships		10:00-11:20
Organiser(s):	UK Collaborative on Development Research (UKCDR) and ESSENCE on Health Research	
Chair(s):	John Kirkland (United Kingdom)	
Presentation(s):	<p>Welcome and introductions John Kirkland, UKCDR (United Kingdom)</p> <p>Presentation of 'Equitable Partnerships Survey – from principles to practice' data Amen Nwosu, UKCDR (United Kingdom)</p> <p>Breakout groups: Theme exploration: enablers, barriers and recommendations All participants</p> <p>Final Discussion and Round Up All participants</p>	
The EDCTP Knowledge Hub: Providing tools and guidance for conducting clinical research		11:20-12:40
Organiser(s):	EDCTP & The Global Health Network (TGHN)	
Chair(s):		
Presentation(s):		
Community engagement/good participatory practice		12:40-14:00
Organiser(s):		
Chair(s):		
Presentation(s):		
Symposia		10:00-12:00
Clinical trial coordination during the COVID-19 pandemic: lessons learned		10:00-11:00
Organiser(s):	Clinical Research Initiative for Global Health (CRIGH)	
Chair(s):	Øyvind Melien (Norway) and <i>Marieme Ba (Senegal)</i>	
Presentation(s):	<p>Global coordination of COVID19 therapeutic and vaccine research Ana Maria Henao, World Health Organization (WHO, Switzerland)</p> <p>The ANTICOV outpatient multinational trial in Africa <i>Nathalie Strub-Wourgraff, Drugs for Neglected Diseases Initiative (DNDi, Switzerland)</i></p> <p>Breakthrough for living evidence and guidance through the COVID-19 pandemic: how can we optimize collaboration with trialists in the evidence ecosystem? Per Olav Vandvik, MAGIC Evidence Ecosystem Foundation (Norway)</p> <p>Coordination mechanisms for COVID-19 trials Jacques Demotes, European Clinical Research Infrastructure Network (ECRIN)/CRIGH (France)</p>	
Networking for synergies in Southern Africa: The TESA consortium & industry perspective		11:00-12:00

Organiser(s):	Manhiça Foundation/Manhica Health Research Center (FM-CISM)	
Chair(s):	Francisco Saúte (Mozambique) and Nuria Casamitjana (Spain)	
Presentation(s):	<p>Southern Africa Network of Excellence, TESA: Capacity Building and Regional Assets for Clinical Trial in partnership with Europe Rodrigues Matcheve, Manhiça Foundation/ Manhiça Health Research Centre (FM-CISM, Mozambique)</p> <p>The South African Tuberculosis Vaccine Initiative: a development of new and effective vaccination strategies against tuberculosis Virginie Rozot, University of Cape Town Lung Institute (UCT LI, South Africa)</p> <p>HIV Early Treatment - Botswana Harvard and Partnership's contribution to clinical trials in the context of the TESA consortium Sikhulile Moyo, Botswana Harvard Partnershio (BHP, Botswana)</p> <p>TESA Consortium Strengthening Institutions in South Africa for Developing Research Capacities on sites with less clinical research traditions Jocelyne Vascolcelos, Centro de Investigação em Saude de Angola (CISA, Angola)</p>	
Other meetings		
Fourth Clinical Research Initiative for Global Health (CRIGH) General Assembly 2021 <i>By invitation only</i>		12:00-14:00
ESSENCE Members meeting <i>By invitation only</i>		14:00-16:00
EDCTP Fellows meeting		13:00-16:45